Featured

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day

August 18, 2025

IDEAYA Biosciences, Inc. announced the agenda for its 10-year anniversary R&D Day on September 8, 2025. The event will feature presentations on the c...

Clinical trial Updates

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day

IDEAYA Biosciences, Inc. announced the agenda for its 10-year anniversary R&D Day on September 8, 2025. The event will feature presentations on the c...

August 18, 2025

ZyVersa Therapeutics Highlights Data on Kidney Lipotoxicity in Diabetic Kidney Disease

ZyVersa Therapeutics announced data highlighting the critical need for therapies targeting kidney lipotoxicity in diabetic kidney disease (DKD). The ...

August 15, 2025

Largest-Ever Sickle Cell Disease Study Completed, Paving Way for New Treatments

Fifty1 AI Labs, in collaboration with The Gates Foundation and leading universities, has completed the largest-ever study of Sickle Cell Disease (SCD)...

August 15, 2025

Avant Technologies and Ainnova Tech Enhance Patient Recruitment for Diabetic Retinopathy AI Platform Clinical Trial

Avant Technologies and its joint venture partner, Ainnova Tech, announced an enhanced patient recruitment strategy for their Vision AI platform clinic...

August 13, 2025

Ocugen Announces Positive EMA Scientific Advice for OCU410ST Gene Therapy for Stargardt Disease

Ocugen, Inc. announced positive scientific advice from the European Medicines Agency (EMA) regarding the approval pathway for OCU410ST, a modifier gen...

August 13, 2025

Spectral Medical's Tigris Trial Shows Positive Results for PMX in Endotoxic Septic Shock

Spectral Medical and Vantive announced positive topline results from the Tigris Phase 3 trial evaluating Polymyxin B Hemoadsorption (PMX) for endotoxi...

August 13, 2025

Lilly's Oral GLP-1 Agonist, Orforglipron, Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial of orforglipron, an investigational oral GLP-1 receptor agoni...

Cassava Sciences Reports Positive Preclinical Study of Simufilam for TSC-Related Epilepsy

Cassava Sciences announced positive preclinical results for simufilam in a mouse model of tuberous sclerosis complex (TSC)-related epilepsy. The stud...

Praxis Precision Medicines Announces Positive Phase 2 Results for Vormatrigine in Focal Onset Seizures

Praxis Precision Medicines announced positive topline results from the Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures. T...

Akebia Initiates Post-Marketing Study for Vafseo® (vadadustat) in CKD Anemia

Akebia Therapeutics announced the initiation of VOCAL, a post-marketing study evaluating the efficacy and safety of Vafseo® (vadadustat) administered ...

NeuroStar TMS Shows Efficacy in Treating Depression in Adolescents and Young Adults

Neuronetics, Inc. announced the publication of real-world data in JAACAP Open demonstrating the effectiveness of NeuroStar TMS therapy in adolescents ...

Research Advances from the 2025 Alzheimer's Association International Conference

The Alzheimer's Association International Conference® 2025 (AAIC®) presented new research on Alzheimer's disease and other dementias. Key findings in...

Anika Therapeutics Announces Topline Results from Hyalofast® Phase III Cartilage Repair Study

Anika Therapeutics announced topline results from its U.S. pivotal Phase III FastTRACK clinical trial of Hyalofast, a hyaluronic acid scaffold for car...

Neuvivo Secures FDA Alignment for NP001 ALS Treatment and Appoints Dr. John Curnutte to Board

Neuvivo, Inc., a late-stage biopharmaceutical company, announced it has reached an agreement with the FDA on the regulatory pathway for NP001, an immu...

VYNE Therapeutics' Phase 2b Repibresib Gel Trial for Vitiligo Misses Primary Endpoint

VYNE Therapeutics announced topline results from its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The trial, involving 177 subje...

Tenaya Therapeutics Receives Positive Safety Reviews for TN-201 and TN-401 Gene Therapy Trials

Tenaya Therapeutics announced positive safety reviews from independent Data Safety and Monitoring Boards (DSMBs) for its two cardiovascular gene thera...

Atossa Therapeutics Receives Positive FDA Feedback for (Z)-Endoxifen in Metastatic Breast Cancer

Atossa Therapeutics announced positive feedback from the FDA regarding its proposed dose optimization trial of (Z)-endoxifen for ER+/HER2- metastatic ...

TauGen Files Patent Application for Novel TBI Drug Candidates

TauGen, LLC, in collaboration with CereMark Pharma, has filed a US patent application for a new class of drug candidates targeting traumatic brain inj...

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet AMD

EyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIA trial evaluating DURAVYU™ for wet age-related macular degenerati...

Lilly's Jaypirca (pirtobrutinib) Meets Primary Endpoint in Phase 3 CLL/SLL Trial

Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent BTK...

Moderna Announces Data Presentation at ESMO Congress 2025

Moderna announced that three abstracts on its investigational mRNA therapeutics will be presented at the 2025 European Society for Medical Oncology (E...

Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced positive topline data from the open-label Phase 2 clinical trial (ATH434-202) of ATH434 in patients with multiple syst...

Fulcrum Therapeutics Announces Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). Th...

Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia

Serina Therapeutics announced the advancement of SER-270 (POZ-VMAT2i), a novel, once-weekly injectable VMAT2 inhibitor, for treating tardive dyskinesi...

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Uveal Melanoma

IDEAYA Biosciences announced that data from a Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal melanoma will be presented at the 20...

GH Research Announces Global Pivotal Program Plans for GH001 and GH002

GH Research PLC provided updates on its clinical-stage biopharmaceutical programs. The company announced a response from the FDA regarding its Invest...

Xenetic Biosciences Expands Collaboration to Advance DNase-Based Oncology Platform

Xenetic Biosciences announced the expansion of its research collaboration with The Scripps Research Institute (TSRI) to further develop its DNase I-ba...

Diakonos Oncology Initiates Phase 2 Trial of DOC1021 for Glioblastoma

Diakonos Oncology announced the first patient has been dosed in a Phase 2 clinical trial evaluating DOC1021, a novel patient-derived double-loaded den...

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day

IDEAYA Biosciences will host an R&D Day on September 8, 2025, to present clinical data updates across its pipeline and outline its future growth strat...

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results for ILUVIEN in Diabetic Macular Edema

ANI Pharmaceuticals announced results from the NEW DAY clinical trial evaluating ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic ma...

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax announced positive topline results from its Phase 3 ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer,...

Oruka Therapeutics Announces IND Clearance for Phase 2a Trial of ORKA-001 in Psoriasis

Oruka Therapeutics announced that the FDA cleared its Investigational New Drug (IND) application for a Phase 2a trial (EVERLAST-A) of ORKA-001, a long...

UroGen's ZUSDURI Shows Long-Term Efficacy in Non-Muscle Invasive Bladder Cancer

UroGen Pharma announced the publication of five-year long-term extension study results from the Phase 2b OPTIMA II trial. The study evaluated ZUSDURI...

Tiziana Life Sciences Announces Promising Immunologic Findings of Nasal Foralumab in Alzheimer's Disease

Tiziana Life Sciences announced compelling immunologic findings from a moderate Alzheimer's Disease patient treated with intranasal foralumab. Transc...

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...

Renovaro's Genetically Engineered Dendritic Cell Therapy Shows Potent Anti-Tumor Efficacy in Preclinical Study

Renovaro Biosciences announced the publication of a peer-reviewed study in *Vaccines* demonstrating the significant anti-tumor efficacy of its next-ge...

Ocugen Initiates Phase 2/3 Trial for Stargardt Disease Gene Therapy

Ocugen, Inc. announced the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a novel modifier gene therapy for Starg...

Keros Therapeutics Initiates Phase 3 Trial of Elritercept for MDS

Keros Therapeutics announced the first patient dosing in the Phase 3 RENEW clinical trial of elritercept for adults with transfusion-dependent anemia ...

OKYO Pharma's Urcosimod Shows Promising Phase 2 Results for Neuropathic Corneal Pain

OKYO Pharma announced positive top-line data from its Phase 2 trial of urcosimod for treating neuropathic corneal pain (NCP). The 18-patient trial sh...

Oragenics Announces U.S. Manufacturing Agreement for ONP-002 Concussion Treatment

Oragenics, Inc. has partnered with Sterling Pharma Solutions for the Good Manufacturing Practice (GMP) production of ONP-002, its lead drug candidate ...

NervGen Announces Leadership Transition and Positive Chronic Spinal Cord Injury Trial Results for NVG-291

NervGen Pharma Corp. announced a leadership transition with Dr. Adam Rogers appointed as Interim CEO, following the positive topline results from the ...

Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program

Voyager Therapeutics announced a new wholly-owned Alzheimer's disease (AD) program targeting apolipoprotein E (APOE), a major genetic risk factor for ...

Avant Technologies and Ainnova Complete Pivotal FDA Meeting for Vision AI Diabetic Retinopathy Platform

Avant Technologies and its JV partner, Ainnova, announced the completion of a pre-submission meeting with the U.S. FDA regarding Ainnova's Vision AI p...

Neurocrine Biosciences Presents CAHtalog Registry Analysis at ENDO 2025

Neurocrine Biosciences announced results from a new analysis of the CAHtalog registry, showing that most patients with classic congenital adrenal hype...

Palatin Announces Positive Preclinical Data for Oral MC4R Agonist PL7737 in Obesity

Palatin Technologies announced positive preclinical results for PL7737, an oral MC4R agonist, demonstrating significant weight loss in obese rodent mo...

Danish Study Finds No Link Between Aluminum in Vaccines and 50 Health Conditions

A large-scale Danish register-based study involving over 1 million children found no association between aluminum in childhood vaccines and 50 health ...

Monteris Medical Announces Positive JAMA Neurology Publication on NeuroBlate System for Epilepsy

Monteris Medical announced the publication of a landmark study in JAMA Neurology demonstrating the safety, durability, and efficacy of laser interstit...

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...

Takeda's Oveporexton Shows Positive Phase 3 Results for Narcolepsy Type 1

Takeda announced positive topline results from two pivotal Phase 3 studies (FirstLight and RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1...

MiNK Therapeutics Announces Complete Remission in Metastatic Testicular Cancer Using iNKT Cell Therapy

MiNK Therapeutics announced the publication of a case report in *Oncogene* showing complete and durable remission in a patient with metastatic, treatm...

Cerevance to Present Phase 1 Data on CVN293, a KCNK13 Inhibitor, at AAIC 2025

Cerevance announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025. Key presentations include Phase 1 dat...

KALA BIO Completes Enrollment in CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect

KALA BIO announced the completion of patient enrollment in the CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secreto...

Silexion Therapeutics Announces Positive Preclinical Results for SIL204 in Lung Cancer

Silexion Therapeutics announced positive preclinical data showing SIL204's significant efficacy in human lung cancer cell lines. SIL204, an RNA inter...

Cizzle Bio Submits NIH Grant for Lung Cancer Biomarker Blood Test

Cizzle Bio, a biotechnology company, submitted a grant application to the NIH for a two-year study validating its CIZ1B biomarker for early-stage lung...

MediView Launches Multicenter Study for XR90 Surgical Navigation System in Soft Tissue Biopsy

MediView has initiated a multicenter clinical study to evaluate the XR90 Holographic Surgical Navigation system's effectiveness in percutaneous soft t...

Plus Therapeutics Announces Initial Patient Treatment in REYOBIQ™ Leptomeningeal Metastases Dose Optimization Trial

Plus Therapeutics announced the treatment of the first patients in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) in l...

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast Cancer

BriaCell Therapeutics Corp. announced updated survival data from its Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC...

Caris Assure® Blood-Based Assay Shows Promise for Multi-Cancer Early Detection and Monitoring

Caris Life Sciences announced a study published in Scientific Reports demonstrating the accuracy and clinical utility of its Caris Assure® blood-based...

MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia

MapLight Therapeutics has begun a Phase 2 clinical trial (ZEPHYR) to assess the efficacy, safety, and tolerability of ML-007C-MA, a novel M1/M4 muscar...

Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity

Ascletis Pharma announced the first participants have been dosed in a Phase IIa clinical trial (NCT07002905) evaluating ASC30, a novel small molecule ...

Soleno Therapeutics Announces Presentations on VYKAT™ XR for Prader-Willi Syndrome at ENDO 2025

Soleno Therapeutics announced that two presentations featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets for the treatment of hyp...

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma

OS Therapies announced positive one-year event-free survival (EFS), overall survival, and safety data from its Phase 2b trial of OST-HER2 in patients ...

Clene Provides Regulatory Update on CNM-Au8 for ALS and MS

Clene, Inc. announced a positive Type C meeting with the FDA regarding its statistical analysis plan for CNM-Au8 in ALS patients. The FDA provided co...

Klotho Neurosciences Advances Manufacturing of ALS Gene Therapy KLTO-202

Klotho Neurosciences announced it is progressing with manufacturing and process development for KLTO-202, a gene therapy targeting amyotrophic lateral...

MeCo Score: A Novel Biomarker for Predicting Response to Antifibrotic Therapy in Breast Cancer

A multinational study published in the journal *Cancers* reveals that the MeCo Score, a novel biomarker, quantifies mechanical conditioning in breast ...

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment

Artelo Biosciences announced positive results from its first-in-human Phase 1 study of ART26.12, a novel, orally administered FABP5 inhibitor for pers...

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna announced positive Phase 3 results for its seasonal influenza vaccine candidate, mRNA-1010. The study demonstrated a 26.6% higher relative va...

Edgewise Therapeutics Announces Positive Sevasemten Results for Becker and Duchenne Muscular Dystrophy

Edgewise Therapeutics reported positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. In Becker MD, open-label da...

DBV Technologies Begins Phase 3 Safety Study for Viaskin Peanut Patch in Peanut-Allergic Toddlers

DBV Technologies announced the first subject has been screened in its COMFORT Toddlers study, a Phase 3 supplemental safety study evaluating the Viask...

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced that it received a Special Protocol Assessment Agreement from the FDA for ADX-2191, a novel formulation of methotrexate...

GeneDx's SeqFirst Study Shows Rapid Genomic Testing Significantly Improves Pediatric Diagnosis

GeneDx announced data from the SeqFirst study, conducted in partnership with Seattle Children's, demonstrating the effectiveness of rapid exome sequen...

Oncotelic Therapeutics Announces Publication Showing TGFB2 Methylation as Positive Prognostic Marker in Pancreatic Cancer

Oncotelic Therapeutics announced the publication of a study in the *International Journal of Molecular Sciences* showing that TGFB2 gene methylation i...

ONCare Alliance and Exigent Research Launch Outpatient Bispecifics Cancer Treatment Program

ONCare Alliance and Exigent Research have launched a groundbreaking outpatient bispecific antibody program for cancer treatment. This program, develo...

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

Alafair Biosciences announced the enrollment of the first patient in a multi-center study evaluating VersaWrap®, a bioresorbable tendon protector, for...

Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBD

Vial, a clinical-stage biotechnology company, announced the first-in-human dosing of its novel, subcutaneous, half-life extended monoclonal antibody t...

Enterra Medical Initiates NAVIGATE Study for Gastric Electrical Stimulation (GES) in Chronic Nausea

Enterra Medical has launched the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) for treating chronic ...

Immunic Reports Positive Long-Term Data for Vidofludimus Calcium in MS

Immunic, Inc. announced positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relaps...

Qlaris Bio to Present New Data on QLS-111 for Glaucoma at World Glaucoma Congress

Qlaris Bio announced that new clinical and preclinical data on its lead investigational compound, QLS-111, will be presented at the 2025 World Glaucom...

Novo Nordisk Advances Amycretin, an Obesity Medication, to Phase 3 Clinical Development

Novo Nordisk announced positive results from two early-phase clinical trials of amycretin, a novel investigational obesity treatment, published in The...

Compass Pathways' COMP360 Psilocybin Shows Positive Phase 3 Results for Treatment-Resistant Depression

Compass Pathways announced positive top-line results from its Phase 3 COMP005 trial evaluating COMP360, a synthetic psilocybin formulation, for treatm...

Soleno Therapeutics Announces Presentations on Diazoxide Choline for Prader-Willi Syndrome at International Conference

Soleno Therapeutics announced multiple presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference. The presentations wi...

Poxel SA Highlights Imeglimin's Potential at ADA 2025

Poxel SA announced that five presentations on the therapeutic potential of Imeglimin (TWYMEEG®), a first-in-class treatment for type 2 diabetes, will ...

UCB Presents Thymidine Kinase 2 Deficiency (TK2d) Research at UMDF 2025 Conference

UCB presented new research on thymidine kinase 2 deficiency (TK2d) at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference. The present...

Indivior Presents Data on SUBLOCADE for Opioid Use Disorder in High Fentanyl Users

Indivior presented new data at the College on Problems of Drug Dependence (CPDD) meeting, showing that a higher dose (300mg) of SUBLOCADE (buprenorphi...

Telomir Pharmaceuticals' Telomir-1 Shows Promise in Preventing Cellular Aging in Progeria

Telomir Pharmaceuticals announced preclinical data showing its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines. Telo...

Tevogen Updates Development of AI-Powered EBV-Specific T Cell Therapy

Tevogen Bio Holdings Inc. announced an update on its development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associat...

Spyre Therapeutics to Report Phase 1 Interim Results for SPY002 Anti-TL1A Antibody

Spyre Therapeutics announced that it will report interim results from Phase 1 healthy volunteer trials for its SPY002 program, a novel half-life exten...

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

AbbVie announced that the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic s...

Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt Disease

Ocugen, Inc. announced that the U.S. FDA has cleared an Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory clinical...

Lyell Immunopharma Announces Positive Clinical Data for LYL314 in Large B-cell Lymphoma

Lyell Immunopharma announced positive Phase 1/2 clinical trial data for LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, in patients with relaps...

Breathe BioMedical Expands Multi-Center Breast Cancer Breath Test Trial

Breathe BioMedical announced the launch of the second site in its multi-center observational study evaluating a breath test for early breast cancer de...

Spyre Therapeutics Announces Positive Phase 1 Results for Anti-TL1A Antibody Programs and Phase 2 Clinical Development Plans

Spyre Therapeutics announced positive interim Phase 1 results for SPY002 and SPY072, two investigational, extended half-life monoclonal antibodies tar...

Hengrui and Kailera Present Clinical Data for HRS9531 and HRS-7535 at ADA 2025

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced the presentation of six abstracts at the American Diabetes Association's 85th Scien...

KalVista Pharmaceuticals Presents Positive Data on Sebetralstat for On-Demand HAE Treatment

KalVista Pharmaceuticals announced positive data from the KONFIDENT-S trial at the EAACI Congress 2025, showcasing sebetralstat's efficacy as an oral,...

Novo Nordisk Advances Amycretin for Weight Management to Phase 3

Novo Nordisk announced its advancement of both subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision ...

ITM to Present COMPETE Trial Data at SNMMI 2025 Annual Meeting

ITM Isotope Technologies Munich SE announced that it will present further analysis from its completed Phase 3 COMPETE trial at the SNMMI 2025 annual m...

Promising Antileukemic Activity of Bleximenib in Combination Therapy for Acute Myeloid Leukemia

Johnson & Johnson announced positive Phase 1b data for bleximenib, a menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid...

Schrödinger Reports Encouraging Phase 1 Data for SGR-1505 in Relapsed/Refractory B-cell Malignancies

Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...

BIMZELX® (bimekizumab) Shows Lasting Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis After Three Years

UCB announced three-year data from Phase 3 trials and open-label extensions showing sustained efficacy of BIMZELX® (bimekizumab) in treating adults wi...

Vaxart's Second-Generation Norovirus Vaccine Shows Significantly Increased Antibody Responses in Phase 1 Trial

Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine. The trial...

Home/KnloSights/clinical trial updates